TEK and neoplasm: The results of this present study, demonstrating that inhibition of the angiopoietin/Tie2 axis with the preclinical version of Trebananib (mL4-3 and L1-7 (N)) upregulates immunologically relevant molecules and increases antigen-specific lysis of tumor cells, support the combination of Ang1 and Ang2 inhibitors such as Trebananib with cancer immunotherapy.